The data includes findings from the CONNECT2 clinical trial program as well as information on patients and healthcare professionals' real-world use of the smart inhaler system.
The Digihaler System is the first and only smart inhaler system with built-in sensors that provide objective inhaler event data to help patients and their doctors support asthma management and develop personalized treatment plans.
The data was featured in five posters, which highlighted:
Real-world Digihaler System usage patterns for patients
The relationship between medication adherence and patients' voluntary responses to a daily self-assessment feature
Barriers, facilitators, and HCP recommendations related to implementation of digital inhaler technology
Digihaler is a digital health system comprised of an electronic multi-dose dry powder smart inhaler, connected app, Digital Health Platform cloud solution and dashboard.
Digihaler inhalers have built-in flow sensors that detect, record and store objective data showing how often and how well patients use their inhalers, as measured by inspiratory flow.
Patients are able to view their data on the Digihaler app, including inhaler use patterns over time, and can share it with a healthcare provider to facilitate dialogue and personalize treatment discussions.
Healthcare providers can also monitor the data on a dashboard with patient permission.
As per the US Food and Drug Administration approved label, there is no evidence that the use of the app leads to improved clinical outcomes, including safety and efficacy.
The CONNECT clinical program evaluated the potential impact of Digihaler System on patient-provider interactions, adherence over time, inhaler technique and frequency of short-acting beta agonist use.
The CONNECT2 trial was conducted to assess the role of both the ProAir Digihaler (albuterol sulfate) inhalation powder and AirDuo Digihaler (fluticasone propionate and salmeterol) inhalation powder in the treatment of asthma as part of the Digihaler System.
CONNECT2 was a 24-week open-label, multicenter, randomized, parallel group study that evaluated the impact of this Digihaler System on asthma management compared to standard of care in 427 patients with asthma.
Participants in the SoC group continued treatment with their current SoC asthma maintenance and reliever medications.
Digihaler integrated inhalers transmit data wirelessly to a smartphone application, which allows for inhaler event tracking.
The App includes a voluntary, non-respiratory-specific DSA. The DSA includes questions asking how a patient is feeling on a three-point scale ranging from sad to neutral to happy.
The two CONNECT2 analyses that will be presented at AAAAI explore:
The relationship between SABA use and patient self-assessment responses
The relationship between medication adherence and patient self-assessment responses
Real-World Digital Health Platform Analysis
The Digihaler Digital Health Platform allows patients to track their inhaler events, and inhaler use, which is recorded as an event when the cap is opened or a patient inhales. The objective data is collected in the App and can be shared with physicians to help them make more informed treatment decisions.
Celltrion USA submits CT-P39 Biologics License Application to FDA
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Allergy Therapeutics reports positive G306 Phase III trial results for Grass MATA MPL
NeoImmuneTech's NT-I7 receives US FDA Orphan Drug Designation
Allergy Therapeutics reports positive interim results for G306 Phase III trial
Amytrx Therapeutics names new directors
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID